• Log In
  • Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar

Mukherjee Labs Preclinical Imaging

Design and Development of Novel Imaging Methods for Early Diagnosis of Diseases

  • Mukherjee Labs – Preclinical Imaging
  • Research
    • Biomarkers Research and Development
    • Radiopharmaceutical Research
    • Pharmacology and Neuroscience
    • Autoradiography
    • Small Animal PET Imaging
    • Small Animal CT Imaging
    • Small Animal SPECT/CT
    • Human Brain & Whole Body PET Imaging
    • Bioluminescence and Fluorescence Optical Imaging
    • Data Sharing
  • People
    • Current Members
    • Former Members
  • Publications
    • Meeting Presentations
    • Schizophrenia
    • Alzheimer’s Disease
    • Parkinson’s Disease
    • Cancer
    • Diabetes & Obesity
  • News
    • UROP Symposium May 2025
    • Student Excellence in Research April 2025
    • Focused Ultrasound machine Feb 2025
    • UROP Symposium May 2024
    • Inveon Embedded PET/CT April 2024
    • Tau Imaging Research February 2024
    • New Hot Cells Installed May 2023
    • UROP UCI Symposium May 2023
    • Letter from US Congress; August 16, 2022
    • SNMMI 2022, JUNE 11-14
    • UROP Symposium May 2022
    • NRM 2021 December 14-16
    • Society for Neuroscience Mtg Nov 2021
    • WMIC, October 5-8, 2021
    • SNMMI Annual Meeting, June 12-15, 2021
    • Flotaza for Alzheimer’s disease
    • UROP UCI Symposium_ May 21, 2021
    • GE TracerLab FXN Installed 12/01/2020
    • New DCE Mini Hot Cell Installed 11/11/2020
    • World Molecular Imaging Conference (WMIC), 10/7/2020
    • New Inveon SPECT/CT Scanner Installed 9/23/2020
    • SNMMI Virtual Annual Meeting 2020, July 11-14
    • Metz Lectures, University of Chicago, Feb 4 and 5, 2020
    • 5th Int Symposium on Acetylcholine, Sept 27-29, 2019
    • SNMMI Annual Meeting, June 22-25, 2019
    • UROP UCI Symposium_ May 18, 2019
    • UROP UCI Symposium_ May 19, 2018
    • AALAS Imaging Workshop May 9, 2018
    • New Website
  • Support
  • Contact Us
You are here: Home / Mukherjee Lab – Preclinical Imaging / Research

Research

Biomarkers research and development

Molecular targeting of specific receptors, transporters, enzyme s and other biomarkers  are carried out by identifying and/or designing small molecules that can be radiolabeled with radioisotopes for PET or SPECT imaging.  Cellular and molecular markers  (biomarkers) that may be potential indicators of disease progression are sought out for developing  imaging probes.  A dysregulation of the biomarker or a loss in the biomarker or an increase in the levels of the biomarker may be detectable by an in vivo imaging probe and assist in diagnosis of disease as well as treatment planning.  Once a molecular target and/or  biomarker is  identified, the process of small molecule design and synthesis is undertaken. This  approach has been used successfully in our laboratories over the last two decades  in optimizing imaging agents such as Fallypride and Desmethoxyfallypride  for  dopamine D2/D3 receptors, Mefway for  serotonin 5HT1a receptors, Nifene for nicotinic  receptors, all of which have now been taken to human studies.

 

Radiopharmaceuticals Production

Molecules to be radiolabeled are identified based on the binding and selectivity of the small molecule to the molecular targets and/or biomarker.  Generally speaking, design of a suitable small molecule takes into consideration the ability to readily and rapidly radiolabel the molecule with radioisotopes such as carbon-11, fluorine-18, iodine-123.  Automated radiosynthesis units are used to develop the radiolabeling methods, develop procedures of purification and quality control and assurance is validated as in 18F-fallypride and 11C-fallypride.  A standard operating procedure (SOP) for the particular radiopharmaceutical is developed. Subsequently the radiopharmaceutical  is taken to in vitro and in vivo preclinical testing.

 

Pharmacology and Neuroscience

Pharmacological testing involves measurement of binding affinities of the new compounds for the various targets sites, including receptors, transporters and other protein targets.  Homogenate binding assays and autoradiographic methods using the Cyclone phosphor imager are used and data is analyzed using various programs such as Optiquant, KELL and Grafit.  In vivo imaging, ex vivo imaging and autoradiographic studies are carried out to study neurotransmitter- receptor interactions like dopamine and drug interactions like clozapine.  Studies are carried out with various labeled compounds (tritium, carbon-11, fluorine-18, iodine-123, iodine-124, gallium-68 and others).

 

Small animal PET Imaging

A state of the art Inveon Dedicated PET scanner from Siemens with a high-resolution of 1.4 mm is available for small animal studies. It can do whole body imaging of rodents, rabbits and other small animals. The facility is equipped to carry out detailed in vivo and ex vivo studies of various biomarkers.

 

Small animal CT Imaging

The facility is equipped with a state of the art Inveon Multimodality (MM) CT  from Siemens, which has a resolution of up to 30 microns. The high resolution of the CT allows various applications for orthopedics, cardiology, oncology and others. The Inveon PET and CT are installed in tandem and can be used to carry out PET/CT imaging.

 

Large animal PET

Preclinical Imaging has unique opportunities for translational research. A high-resolution (4 to 4.5 mm) ECAT HR+ whole-body research scanner is available for human and large animal research. This equipment  allows rapid transition from animal studies to human research studies. This facility if fully equipped to carry out various studies of neuroscience, oncology, diabetes, cardiology and others. In addition to the capabilities of preclinical imaging facility, translational research is enhanced by collaborations with various Centers and Departments at UCI. Multimodality imaging is an area of research which will be strengthened by ongoing work at other Centers at UCI.

 

Optical Imaging

In vivo fluorescence imaging is being used to optimize biomarkers for PET and assist in longitudinal studies. An in vivo Kodak imaging system F (Image Station 4000MM) is used for these studies. The system features 5-position excitation filter slider with two excitation filters of choice, 4-position emission filter wheel with two proprietary wide-angle emission filters of choice, external 150-watt halogen illumination source and mounted fiber-optic light guides, PC computer with 17-inch flat-panel monitor, KODAK Molecular Imaging Software. The CCD camera presents 4.2 megapixel resolution, true 16-bit imaging and high sensitivity.

 

 

Primary Sidebar

Translational PET

Inveon PET

Inveon CT

Inveon SPECT/CT

ECAT HR+ PET

Molecular Imaging

Mukherjee Labs

Preclinical Imaging
Radiological Sciences
University of California Irvine
Irvine, CA 92697-5000
email: j.mukherjee@uci.edu
Tel: 949-824-2018

© 2025 UC Regents